Sterol 14-Demethylase Inhibitors for Trypanosoma cruzi Infections

  • Frederick S. Buckner
Part of the Advances In Experimental Medicine And Biology book series (AEMB, volume 625)


Chagas disease is caused by infection with the protozoan pathogen, Trypanosoma cruzi. The only approved therapeutics for treating Chagas disease are two nitroheterocydic compounds (benznidazole and nifurtimox) that are suboptimal due to poor curative activity for chronic Chagas disease and high rates of adverse drug reactions. Sterol 14-demethylase inhibitors include azole antifungal drugs such as ketoconazole, fluconazole, itraconazole, and others. The first reports of potent activity of azole antifungal drugs against Trypanosoma cruzi came out about 25 years ago. Since then, a sizeable literature has accumulated on this topic. Newer triazole compounds such as posaconazole and D0870 have been shown to be effective at curing mice with chronic Trypanosoma cruzi infection. Small clinical studies with ketoconazole or itraconazole in humans with chronic Chagas disease have not demonstrated significant curative activity. However, there is good reason for optimism that newer compounds with greater potency and improved pharmacokinetic properties might be more efficacious. Data have been published demonstrating synergistic activity of azole drugs with various other compounds, indicating that combination chemotherapy may be an effective strategy as this field moves ahead. In light of the near absence of adequate therapeutics for curing patients with chronic Chagas disease, additional effort to develop better drugs needs to be a priority.


Antimicrob Agent Trypanosoma Cruzi Sterol Biosynthesis Azole Drug Sterol Biosynthesis Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Docampo R, Moreno SN, Turrens JF et al. Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Mol Biochem Parasitol 1981; 3:169–80.PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization. Control of Chagas’ disease. WHO Tech Rep Ser 1991; 811:1–93.Google Scholar
  3. 3.
    Eisen H, Petry K, Van Voorhis WC. The origin of autoimmune pathology associated with Trypanosoma cruzi infection. In: Van Der Ploeg LHT, Cantor CR, Voegel HJ, eds. Immune Recognition and Evasion: Molecular Aspects of Host-Parasite Interaction. London: Academic Press Inc., 1990:91–103.Google Scholar
  4. 4.
    Viotti R, Vigliano C, Armenti H et al. Treatment of chronic Chagas’ disease with benznidazole: Clinical and serological evolution of patients with long-term follow-up. Am Heart J 1994; 127:151–62.PubMedCrossRefGoogle Scholar
  5. 5.
    Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: Controversies and advances. Trends Parasitol 2003; 19:495–501.PubMedCrossRefGoogle Scholar
  6. 6.
    Sosa ES, Segura EL, Ruiz AM et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg 1998; 59:526–29.Google Scholar
  7. 7.
    Pan American Health Organization/World Health Organization. Etiological treatment for Chagas disease. Rev Pat Trop 1998; 28:247–79.Google Scholar
  8. 8.
    Daum G, Lees ND, Bard M et al. Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Yeast 1998; 14:1471–510.PubMedCrossRefGoogle Scholar
  9. 9.
    Lamb DC, Kelly DE, Waterman MR et al. Characteristics of the heterologously expressed human lanosterol 14alpha-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents. Yeast 1999; 15:755–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Fischer RT, Stam SH, Johnson PR et al. Mechanistic studies of lanosterol 14 alpha-methyl demethylase: Substrate requirements for the component reactions catalyzed by a single cytochrome P-450 isozyme. J Lipid Res 1989; 30:1621–32.PubMedGoogle Scholar
  11. 11.
    Rozman D, Stromstedt M, Waterman MR. The three human cytochrome P450 lanosterol 14 alpha-demethylase (CYP51) genes reside on chromosomes 3, 7, and 13: Structure of the two retrotransposed pseudogenes, association with a line-1 element, and evolution of the human CYP51 family. Arch Biochem Biophys. 1996; 333:466–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Lepesheva GI, Nes WD, Zhou W et al. CYP51 from Trypanosoma brucei is obtusifoliol-specific. Biochem 2004; 43:10789–99.CrossRefGoogle Scholar
  13. 13.
    Podust LM, Yermalitskaya LV, Lepesheva GI et al. Estriol bound and ligand-free structures of sterol 14alpha-demethylase. Structure (Camb.) 2004; 12:1937–45.CrossRefGoogle Scholar
  14. 14.
    Hucke O, Gelb MH, Verlinde CL et al. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem 2005; 48:5415–18.PubMedCrossRefGoogle Scholar
  15. 15.
    Walker KA, Kertesz DJ, Rotstein DM et al. Selective inhibition of mammalian lanosterol 14 alpha-demethylase: A possible strategy for cholesterol lowering. J Med Chem 1993; 36:2235–37.PubMedCrossRefGoogle Scholar
  16. 16.
    Vanden Bossche H, Marichal P, Gorrens J et al. Interaction of azole derivatives with cytochrome P-450 isozymes in yeast, fungi, plants and mammalian cells. Pestic Sci 1987; 21:289–306.CrossRefGoogle Scholar
  17. 17.
    Lewis DF. 57 varieties: The human cytochromes P450. Pharmacogenomics 2004; 5:305–18.PubMedCrossRefGoogle Scholar
  18. 18.
    Pont A, Williams PL, Azhar S et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982; 142:2137–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Pont A, Williams PL, Loose DS et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 1982; 97:370–72.PubMedGoogle Scholar
  20. 20.
    Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev 1986; 7:409–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Korn ED, Von Brand T, Tobie EJ. The sterols of Trypanosoma cruzi and Crithidia fasciculata. Comp Biochem Physiol 1969; 30:601–10.PubMedCrossRefGoogle Scholar
  22. 22.
    Docampo R. Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Molec Biochem Parasitol 1981; 3:169–80.CrossRefGoogle Scholar
  23. 23.
    Beach DH, Goad LJ, Holz Jr GG. Effects of ketoconazole on sterol biosynthesis by Trypanosoma cruzi epimastigotes. Biochem Biophys Res Commun 1986; 136:851–56.PubMedCrossRefGoogle Scholar
  24. 24.
    Goad LJ, Berens RL, Marr JJ et al. The activity of ketoconazole and other azoles against Trypanosoma cruzi: Biochemistry and chemotherapeutic action in vitro. Molec Biochem Parasitol 1989; 32:179–90.CrossRefGoogle Scholar
  25. 25.
    Urbina JA, Vivas J, Visbal G et al. Modification of the sterol composition of Trypanosoma (Schizotrypanum) cruzi epimastigotes by delta 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Mol Biochem Parasitol 1995; 73:199–210.PubMedCrossRefGoogle Scholar
  26. 26.
    Lazardi K, Urbina JA, de Souza W. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 1990; 34:2097–105.PubMedGoogle Scholar
  27. 27.
    Liendo A, Visbal G, Piras MM et al. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol Biochem Parasitol 1999; 104:81–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Liendo A, Lazardi K, Urbina JA. In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi. J Antimicrob Chemother 1998; 41:197–205.PubMedCrossRefGoogle Scholar
  29. 29.
    Urbina JA, Lazardi K, Aguirre T et al. Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 1988; 32:1237–42.PubMedGoogle Scholar
  30. 30.
    Urbina JA, Payares G, Contreras LM et al. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: In vitro and in vivo studies. Antimicrob Agents Chemother 1998; 42:1771–77.PubMedGoogle Scholar
  31. 31.
    Buckner FS, Joubert BM, Boyle SM et al. Cloning and analysis of Trypanosoma cruzi lanosterol 14α-demethylase. Mol Biochem Parasitol 2003; 132:75–81.PubMedCrossRefGoogle Scholar
  32. 32.
    Lepesheva GI, Zaitseva NG, Nes WD et al. CYP51 from Trypanosoma cruzi: A phyla-specific residue in the B’ helix defines substrate preferences of sterol 14alpha-demethylase. J Biol Chem 2006; 281:3577–85.PubMedCrossRefGoogle Scholar
  33. 33.
    Buckner F, Yokoyama K, Lockman J et al. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci USA 2003; 100:15149–53.PubMedCrossRefGoogle Scholar
  34. 34.
    McCabe R. Failure of ketoconazole to cure chronic murine Chagas' disease. J Infect Dis 1988; 158:1408–09.PubMedGoogle Scholar
  35. 35.
    Urbina JA, Payares B, Molina J et al. Cure of short-and long-term experimental Chagas’ disease using D0870. Science 1996; 273:969–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Moreira AA, de Souza HB, Amato-Neto V et al. Evaluation of the therapeutic activity of itraconazole in chronic infections, experimental and human, by Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 1992; 34:177–80.PubMedGoogle Scholar
  37. 37.
    Urbina JA, Payares G, Sanoja C et al. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 2003; 21:27–38.PubMedCrossRefGoogle Scholar
  38. 38.
    Urbina JA, Payares G, Sanoja C et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents 2003; 21:39–48.PubMedCrossRefGoogle Scholar
  39. 39.
    Corrales M, Cardozo R, Segura MA et al. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas’ disease. Antimicrob Agents Chemother 2005; 49:1556–60.PubMedCrossRefGoogle Scholar
  40. 40.
    Brener Z. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem Inst Oswaldo Cruz 1993; 88:149–53.PubMedGoogle Scholar
  41. 41.
    Toledo MJ, Bahia MT, Veloso VM et al. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes. J Antimicrob Chemother 2004; 53:1045–53.PubMedCrossRefGoogle Scholar
  42. 42.
    Guedes PM, Urbina JA, de Lana M et al. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother 2004; 48:4286–92.PubMedCrossRefGoogle Scholar
  43. 43.
    Araujo MS, Martins-Filho OA, Pereira ME et al. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas’ disease. J Antimicrob Chemother 2000; 45:819–24.PubMedCrossRefGoogle Scholar
  44. 44.
    Maldonado RA, Molina J, Payares G et al. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas’ disease. Antimicrob Agents Chemother 1993; 37:1353–59.PubMedGoogle Scholar
  45. 45.
    Benaim G, Sanders JM, Garcia-Marchan Y et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 2006; 49:892–99.PubMedCrossRefGoogle Scholar
  46. 46.
    Apt W, Aguilera X, Arribada A et al. Treatment of chronic Chagas’ disease with itraconazole and allopurinol. Am J Trop Med Hyg 1998; 59:133–38.PubMedGoogle Scholar
  47. 47.
    Apt W, Arribada A, Zulantay I et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: The results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 2005; 99:733–41.PubMedCrossRefGoogle Scholar
  48. 48.
    Buckner FS, Verlinde CLMJ, La Flamme AC et al. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase. Antimicrob Agents Chemother 1996; 40:2592–97.PubMedGoogle Scholar
  49. 49.
    McCabe RE, Remmington JS, Araujo FG. In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am J Trop Med Hyg 1986; 35:280–84.PubMedGoogle Scholar
  50. 50.
    McCabe RE, Remington JS, Araujo FG. Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. J Infect Dis 1984; 150:594–601.PubMedGoogle Scholar
  51. 51.
    Urbina JA, Lazardi K, Marchan E et al. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: In vitro and in vivo studies. Antimicrob Agents Chemother 1993; 37:580–91.PubMedGoogle Scholar
  52. 52.
    Urbina JA, Lira R, Visbal G et al. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 2000; 44:2498–502.PubMedCrossRefGoogle Scholar
  53. 53.
    Campos R, Amato NV, Moreira AA et al. Evaluation of the therapeutic activity of fluconazole in acute experimental infection caused by Trypanosoma cruzi. Rev Hosp Clin Fac Med Sao Paulo 1992; 47:174–75.PubMedGoogle Scholar
  54. 54.
    Molina J, Martins-Filho O, Brener Z et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000; 44:150–55.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2008

Authors and Affiliations

  • Frederick S. Buckner
    • 1
  1. 1.Department of MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations